Castration resistant prostate cancer, beyond the usual treatment

Poster Session 61

Monday, 14 March
08:45 - 10:15

Location: Room 14b (ICM, Level 1)

Chairs: T.A. Borkowski, Warsaw (PL)
S. Egawa, Tokyo (JP)
A. Necchi, Milan (IT)

Aims and objectives of this presentation
The treatment Castration Resistant Prostate Cancer has been revolutionised over the years. Understanding its complexity is a major challenge for most urologists. This session will help understand the latest developments in the area.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (+) are 3 minutes in length, followed by 3 minutes for discussion.

Radium-223 (Ra-223) re-treatment (re-tx): Experience from an international, multicenter, prospective study in patients (pts) with castration-resistant prostate cancer and bone metastases (mCRPC)
By: Keizman D.¹, Nordquist L.T.², Mariados N.³, Méndez Vidal M.J.⁴, Thellenberg Karlsson C.⁵, Peer A.⁶, Procopio G.⁷, Frank S.J.⁸, Pulkkanen K.⁹, Severi S.¹⁰, Trigo Perez J.M.¹¹, Schwarzenberger P.¹², Li R.¹³, Sartor O.¹⁴
Institutes: Meir Medical Center, Dept. of Genitourinary Oncology Service, Kfar-Saba, Israel, ²GU Research Network, LLC, Dept. of Medical Oncology, Omaha, Nebraska, United States of America, ³Associated Medical Professionals of New York, PLLC, Dept. of Radiation Oncology, Syracuse, New York, United States of America, ⁴Hospital Universitario Reina Sofia, Dept. of Medical Oncology, Cordoba, Spain, ⁵Cancer Center Norrland University, Dept. of Radiation Sciences, Umeå, Sweden, ⁶Rambam Medical Center, Dept. of Oncology, Haifa, Israel, ⁷Foundation IRCCS National Cancer Institute, Dept. of Medical Oncology, Milan, Italy, ⁸Hadassah Hebrew University Medical Center, Dept. of Oncology, Jerusalem, Israel, ⁹Kuopio University Hospital, Dept. of Oncology, Kuopio, Finland, ¹⁰Romagnolo Scientific Institute For The Study and Care of Cancer – IRST IRCCS, Dept. of Nuclear Medicine Therapeutic, Meldola, Italy, ¹¹Hospital Universitario Virgen De La Victoria, Dept. of Medical Oncology, Malaga, Spain, ¹²Bayer HealthCare, Dept. of Global Clinical Development, Whippany, New Jersey, United States of America, ¹³Bayer HealthCare, Dept. of Global Research & Development Statistics, Whippany, New Jersey, United States of America, ¹⁴Tulane Cancer Center, Dept. of Medicine and Urology, New Orleans, Louisiana, United States of America

Updated long-term efficacy and safety of androgen receptor inhibitor ODM-201 in phase I/II trial
By: Fizazi K.¹, Massard C.¹, Bono P.², Kataja V.³, James N.⁴, Tammela T.⁵, Joensuu H.², Aspegren J.⁶, Mustonen M.V.⁶
Institutes: ¹Institut Gustave Roussy, Dept. of Cancer Medicine, Villejuif, France, ²Helsinki University Central Hospital, Comprehensive Cancer Center, Helsinki, Finland, ³Kuopio University Hospital, Jyväskylä Central Hospital, Kuopio, Finland, ⁴Queen Elizabeth Hospital University Hospitals, Birmingham NHS Foundation Trust, Birmingham, Finland, ⁵Tampere University Hospital, Dept. of Urology, Tampere, Finland, ⁶Orion Corporation Orion Pharma, Research and Development, Espoo, Finland

Statin use and prostate cancer mortality
By: Benzon Larsen S.¹, Skriver C.¹, Dehlendorff C.¹, Jespersen C.², Borre M.³, Nørgård M.⁴, Brasso K.⁵, Andersen K.K.¹, Sørensen H.⁴, Hallas J.⁵, Friis S.¹
Institutes: ¹Danish Cancer Society, Research Centre, Copenhagen, Denmark, ²Viborg Hospital, Dept. of Urology, Viborg, Denmark, ³Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, ⁴
Testosterone bounce predicts cancer specific survival of prostate cancer patients treated with docetaxel therapy  
By: Shuhei K., Sakamoto S., Yamamoto S., Inoue T., Nozumi K., Chiba K., Miyazaki K., Atsushi I., Nagata M.  
Institutes: Yokohama Rosai Hospital, Dept. of Urology, Yokohama City, Kanagawa, Japan, Chiba Univ. Hospital, Dept. of Urology, Chiba City, Chiba, Japan

Effect of PSA response on overall and progression-free survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel (Caba): The non-interventional study QoLiTime  
By: Hammerer P., Al-Batran S-E., Windemuth-Kieselbach C., Hofheinz R-D.  
Institutes: Academic Hospital Braunschweig, Dept. of Urology and Uro-Oncology, Braunschweig, Germany, Nordwest Hospital, Institute of Clinical Research, Frankfurt, Germany, Alcedis GmbH, Dept. of Biometry, Gießen, Germany, University Hospital Mannheim, Interdisciplinary Tumor Center, Mannheim, Germany

Initial clinical experience with 177Lu-PSMA I&T radionuclide therapy in patients with metastatic castration-resistant prostate cancer  
By: Heck M., Retz M., Rauscher I., Scheidhauer K., Maurer T., Storz E., Janssen F., D’Alessandria C., Wester H.-J., Gschwend J.E., Schwaiger M., Tauber R., Eiber M.  
Institutes: Klinikum Rechts der Isar der Technischen Universität München, Dept. of Urology, Munich, Germany, Klinikum Rechts der Isar der Technischen Universität München, Dept. of Nuclear Medicine, Munich, Germany, Technische Universität München, Dept. of Pharmaceutical Radiochemistry, Garching, Germany

Hormonal response after long-term androgen suppression in patients with prostate cancer  
By: Planas Morin J., Celma A., Regis L., Cuadras M., Trilla E., Salvador C., Placer J., Lorente D., Carles J., Suárez C., Morote J.  
Institutes: Hospital Universitari Vall d’Hebron, Dept. of Urology, Barcelona, Spain, Hospital Universitari Vall d’Hebron, Dept. of Oncology, Barcelona, Spain

Real-world treatment patterns and factors influencing the use of bone-targeted agents (BTAs) in combination with emerging therapeutics in patients with prostate cancer and bone-metastases  
Institutes: Chu Brugmann, Dept. Of Medicine, Brussels, Belgium, Kantonsspital Graubünden, Dept. of Oncology, Chur, Switzerland, Adelphi Real World, Bollington, United Kingdom, Amgen Inc., Dept. of Health Economics, Thousand Oaks, United States of America, Amgen (Europe) GmbH, Dept. of Health Economics, Zug, Switzerland

Which factors predict overall survival in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate post-docetaxel?  
Institutes: Ghent University Hospital, Dept. of Urology, Ghent, Belgium, Ghent University Hospital, Dept. of Medical Oncology, Ghent, Belgium, Leuven University Hospital, Dept. of Medical Oncology, Leuven, Belgium, AZ Turnhout, Dept. of Medical Oncology, Turnhout, Belgium, AZ Klinia, Dept. of Medical Oncology, Brasschaat, Belgium, AZ Delta, Dept. of Medical Oncology, Roeselare, Belgium, AZ Imelda, Dept. of Medical Oncology, Bonheiden, Belgium, Institut Jules Bordet, Dept. of Medical Oncology, Brussels, Belgium, OLV Aalst, Dept. of Urology, Aalst, Belgium, Hospital De Jolimont, Dept. of Medical Oncology, Haine Saint Paul, Belgium, Brussels University Hospital, Dept. of Medical Oncology, Brussels, Belgium, Cliniques Universitaires Saint Luc, Dept. of
Abiraterone for castration resistant prostate cancer: Adherence, survival and hospitalization: Analysis of a medical claims database
By: Mohamad Al-Ali B.¹, Madersbacher S.¹, Berger I.²
Institutes: ¹Kaiser-Franz-Josef Spital, Dept. of Urology and Andrology, Vienna, Austria, ²Klinikum Wiener Neustadt, Dept. of Urology and Andrology, Wiener Neustadt, Austria

ARV7 detected by a novel whole-blood RT-PCR assay correlates with outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate (ABI)
By: Todenhöfer T.¹, Azad A.², Gao J.¹, Stewart C.¹, Eigl B.², Stenzl A.³, Black P.¹, Teich M.³, Joshua A.³, Chi K.²
Institutes: University of British Columbia, Vancouver Prostate Centre, Vancouver, Canada, ²British Columbia Cancer Agency, Dept. of Medical Oncology, Vancouver, Canada, ³University of Toronto, Princess Margret Cancer Centre, Toronto, Canada, ⁴Eberhard-Karls-University, Dept. of Urology, Tübingen, Germany

The phase 3 COU-AA-302 study of abiraterone acetate (AA) in men with chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC): Stratified analysis based on pain, prostate-specific antigen (PSA) and Gleason score (GS)
By: Miller K.¹, Carles J.², Gschwend J.E.³, Van Poppel H.⁴, Diels J.⁵, Brookman-May S.D.⁶
Institutes: ¹Charité Berlin, Dept. of Urology, Berlin, Germany, ²Vall D’Hebron University Hospital, Dept. of Medical Oncology, Barcelona, Spain, ³Technical University of Munich, School of Medicine, Munich, Germany, ⁴Katholieke Universiteit Leuven, Dept. of Urology, Leuven, Belgium, ⁵Janssen EMEA, HEMAR, Beerse, Belgium, ⁶Ludwig Maximilians University of Munich, Janssen Research & Development, Munich, Germany